72,588 Shares in AtriCure, Inc. $ATRC Acquired by F m Investments LLC

F m Investments LLC acquired a new position in AtriCure, Inc. (NASDAQ:ATRC) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 72,588 shares of the medical device company’s stock, valued at approximately $2,872,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Oak Harvest Investment Services acquired a new position in AtriCure in the 4th quarter worth approximately $1,484,000. Massachusetts Financial Services Co. MA boosted its stake in AtriCure by 20.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 511,213 shares of the medical device company’s stock worth $20,224,000 after purchasing an additional 86,532 shares during the period. Riverwater Partners LLC boosted its stake in AtriCure by 79.2% in the 3rd quarter. Riverwater Partners LLC now owns 60,322 shares of the medical device company’s stock worth $2,126,000 after purchasing an additional 26,657 shares during the period. Citigroup Inc. boosted its stake in AtriCure by 182.0% in the 3rd quarter. Citigroup Inc. now owns 57,085 shares of the medical device company’s stock worth $2,012,000 after purchasing an additional 36,839 shares during the period. Finally, Semanteon Capital Management LP acquired a new position in AtriCure in the 3rd quarter worth approximately $564,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ATRC shares. Freedom Capital raised shares of AtriCure to a “strong-buy” rating in a research note on Wednesday, April 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $45.00 price objective on shares of AtriCure in a research note on Thursday, February 12th. Citizens Jmp cut their target price on shares of AtriCure from $60.00 to $52.00 and set a “market outperform” rating for the company in a research report on Wednesday, February 18th. Weiss Ratings downgraded shares of AtriCure from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, May 4th. Finally, BTIG Research reiterated a “buy” rating and issued a $54.00 target price on shares of AtriCure in a research report on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, AtriCure currently has an average rating of “Moderate Buy” and an average price target of $48.71.

AtriCure Stock Down 5.5%

ATRC stock opened at $26.28 on Friday. AtriCure, Inc. has a 12-month low of $26.08 and a 12-month high of $43.18. The company has a quick ratio of 2.99, a current ratio of 4.29 and a debt-to-equity ratio of 0.15. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -262.80 and a beta of 1.28. The company has a 50 day moving average of $29.24 and a two-hundred day moving average of $34.28.

AtriCure (NASDAQ:ATRC) last released its earnings results on Tuesday, May 5th. The medical device company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.07. AtriCure had a negative net margin of 0.83% and a positive return on equity of 0.29%. The company had revenue of $141.25 million during the quarter, compared to the consensus estimate of $139.75 million. During the same quarter in the prior year, the firm earned ($0.14) EPS. The company’s revenue was up 14.3% compared to the same quarter last year. AtriCure has set its FY 2026 guidance at 0.000-0.040 EPS. On average, equities analysts anticipate that AtriCure, Inc. will post 0.01 earnings per share for the current fiscal year.

Insider Transactions at AtriCure

In other AtriCure news, insider Vinayak Doraiswamy sold 5,000 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $29.83, for a total value of $149,150.00. Following the completion of the sale, the insider owned 96,875 shares in the company, valued at $2,889,781.25. This represents a 4.91% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.00% of the stock is currently owned by insiders.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.